EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieOpen Access

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

Alex F Herrera iD, Michael LeBlanc, Sharon M Castellino iD, Hongli Li, Sarah C Rutherford, Andrew M Evens iD, Kelly Davison, Angela Punnett, Susan K Parsons, Sairah Ahmed, Carla Casulo, Nancy L Bartlett und 35 weitere

New England Journal of Medicine · 17.10.2024 · 391 (15) · 1379-1389

DOI: 10.1056/nejmoa2405888 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 17.10.2024. Verfasst von Alex F Herrera und 46 weiteren Autor:innen. Beteiligte Einrichtung: From City of Hope Comprehensive Cancer Center, Duarte (A.F.H., M.G.M., J.Y.S.), University of California Davis Comprehensive Cancer Center, Sacrament…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Dacarbazine, Doxorubicin. Die Arbeit wurde bisher 279-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, SeaGen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinDacarbazineDoxorubicinHodgkin DiseaseNivolumabVinblastineAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedYoung AdultIntention to Treat AnalysisKaplan-Meier EstimateNeoplasm StagingProgression-Free SurvivalAged, 80 and overTreatment Outcome

Substanzen

Brentuximab VedotinDacarbazineDoxorubicinNivolumabVinblastine

Autor:innen und Institutionen

  • From City of Hope Comprehensive Cancer Center, Duarte (A.F.H., M.G.M., J.Y.S.), University of California Davis Comprehensive Cancer Center, Sacramento (J.M.T.), and Children's Hospital Los Angeles, Los Angeles (C.F., A.…

ORCID-Profile: Alex F Herrera, Sharon M Castellino, Andrew M Evens, Boyu Hu

Förderung

  • NCI NIH HHS
  • NIH HHS
  • SeaGen
  • Bristol-Myers Squibb
  • National Cancer Institute, National Institutes of Health

Zitieren

APA

Herrera, A. F., LeBlanc, M., Castellino, S. M., Li, H., Rutherford, S. C., Evens, A. M., Davison, K., Punnett, A., Parsons, S. K., Ahmed, S., Casulo, C., Bartlett, N. L., Tuscano, J. M., Mei, M. G., Hess, B. T., Jacobs, R., Saeed, H., Torka, P., Hu, B., …, & Friedberg, J. W. (2024). Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. New England Journal of Medicine, 391(15), 1379-1389. https://doi.org/10.1056/nejmoa2405888

Vancouver

Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. New England Journal of Medicine. 2024;391(15):1379-1389. doi:10.1056/nejmoa2405888

BibTeX
@article{Herrera2024,
  author = {Herrera, Alex F and LeBlanc, Michael and Castellino, Sharon M and Li, Hongli and Rutherford, Sarah C and Evens, Andrew M and Davison, Kelly and Punnett, Angela and Parsons, Susan K and Ahmed, Sairah and Casulo, Carla and Bartlett, Nancy L and Tuscano, Joseph M and Mei, Matthew G and Hess, Brian T and Jacobs, Ryan and Saeed, Hayder and Torka, Pallawi and Hu, Boyu and Moskowitz, Craig and Kaur, Supreet and Goyal, Gaurav and Forlenza, Christopher and Doan, Andrew and Lamble, Adam and Kumar, Pankaj and Chowdhury, Saeeda and Brinker, Brett and Sharma, Namita and Singh, Avina and Blum, Kristie A and Perry, Anamarija M and Kovach, Alexandra E and Hodgson, David and Constine, Louis S and Shields, Lale Kostakoglu and Prica, Anca and Dillon, Hildy and Little, Richard F and Shipp, Margaret A and Crump, Michael and Kahl, Brad and Leonard, John P and Smith, Sonali M and Song, Joo Y and Kelly, Kara M and Friedberg, Jonathan W},
  title = {Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {15},
  pages = {1379--1389},
  doi = {10.1056/nejmoa2405888}
}
Kostenlos starten →